Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2012 Jun;59(6):539–546. doi: 10.1097/FJC.0b013e31824e1b93

Figure 7. AVE0118 prolongs atrial APD and ERP in the presence of acetylcholine (ACh) and effectively terminates ACh-mediated AF.

Figure 7

A: Superimposed action potentials (AP) recorded in control, in the presence of ACh, and ACh plus AVE0118. B: Plot depicts average changes in APD70 and ERP. All data are from pectinate muscle stimulated at a CL of 500 ms. * - p<0.05 vs. control. † p<0.05 vs. ACh. n=5–10. C: Shown are ECG and AP tracings recorded during persistent AF in the presence of ACh alone and following the addition of AVE0118, which terminated the arrhythmia on the 12th minute.